期刊文献+
共找到16篇文章
< 1 >
每页显示 20 50 100
乳腺肿瘤免疫微环境及其在临床免疫治疗中的应用 被引量:1
1
作者 魏忠伟 李付广 《疾病监测与控制》 2019年第5期401-402,410,共3页
免疫系统中存在着很多的免疫细胞,而且这些细胞的激活状态都不相同。对于不同的乳腺肿瘤细胞所受到的免疫细胞浸润程度也会有所不同。这样就为检测乳腺肿瘤的治疗效果提供了一个有效的检测指标。所以研究肿瘤细胞和免疫细胞之间的关系... 免疫系统中存在着很多的免疫细胞,而且这些细胞的激活状态都不相同。对于不同的乳腺肿瘤细胞所受到的免疫细胞浸润程度也会有所不同。这样就为检测乳腺肿瘤的治疗效果提供了一个有效的检测指标。所以研究肿瘤细胞和免疫细胞之间的关系和相互作用就显得十分重要,近年来也成了肿瘤研究中的热门领域。本文将对现在的乳腺肿瘤免疫微环境及其在临床免疫治疗中的应用进行总结为相关的学者和医疗人员提供一些参考。 展开更多
关键词 乳腺肿瘤 免疫微环境 临床免疫治疗 免疫细胞
下载PDF
天然免疫应答清除HBV的作用及其临床免疫治疗的前景 被引量:6
2
作者 王福生 《中华医学杂志》 CAS CSCD 北大核心 2005年第17期1158-1159,共2页
关键词 临床免疫治疗 天然免疫应答 清除 HBV 特异性免疫应答 乙型肝炎 抗肝炎病毒 病毒颗粒 临床恢复 慢性炎症 致病过程 临床进展 抗感染 保护性 肝硬化 抗病毒
原文传递
鼻咽癌的临床免疫治疗
3
作者 杜海军 周玲 曾毅 《中华实验和临床病毒学杂志》 CAS CSCD 北大核心 2009年第6期502-503,共2页
鼻咽癌(NPC)是我国南方一些省(自治区)的常见恶性肿瘤之一。在广东、广西发病率可高达50/10万,在两广一些地区NPC占肿瘤病死率的第一或第二位,是我国重点防治的十大肿瘤之一。放射治疗是鼻咽癌治疗的基本方法,国内外文献报道鼻... 鼻咽癌(NPC)是我国南方一些省(自治区)的常见恶性肿瘤之一。在广东、广西发病率可高达50/10万,在两广一些地区NPC占肿瘤病死率的第一或第二位,是我国重点防治的十大肿瘤之一。放射治疗是鼻咽癌治疗的基本方法,国内外文献报道鼻咽癌5年生存率为50%—60%。中晚期鼻咽癌治疗失败原因多是局部复发和远处转移。 展开更多
关键词 中晚期鼻咽癌 临床免疫治疗 恶性肿瘤 5年生存率 放射治疗 远处转移 局部复发 失败原因
原文传递
口腔扁平苔藓的免疫病理机制和中西医临床免疫治疗 被引量:5
4
作者 孙安迪 《中华口腔医学杂志》 CAS CSCD 北大核心 2009年第7期395-400,共6页
口腔扁平苔藓(orallichenplanus,OLP)的病因复杂,至今未明。OLP的免疫病理机制是什么?是否为自身免疫性疾病?是否有癌变潜能?是否有评估疾病活性的敏感免疫指标?其临床中西医免疫治疗效果如何?都是值得学者们关注的课题。
关键词 临床免疫治疗 免疫病理机制 口腔扁平苔藓 中西医 自身免疫性疾病 免疫指标 治疗效果 OLP
原文传递
白细胞介素-12临床应用研究进展 被引量:12
5
作者 宋舸 袁玫 卢世璧 《中华肿瘤防治杂志》 CAS 2007年第1期75-79,共5页
白细胞介素-12(IL-12)最初称作自然杀伤细胞刺激因子(NKSF)或细胞毒性淋巴细胞成熟因子(CLMF),是一种异二聚体细胞因子。直接使用重组蛋白IL-12或转基因载体都有显著的抗肿瘤作用,它通过诱发NK,NKT和T细胞增殖活化而介导主动和被动免疫... 白细胞介素-12(IL-12)最初称作自然杀伤细胞刺激因子(NKSF)或细胞毒性淋巴细胞成熟因子(CLMF),是一种异二聚体细胞因子。直接使用重组蛋白IL-12或转基因载体都有显著的抗肿瘤作用,它通过诱发NK,NKT和T细胞增殖活化而介导主动和被动免疫保护反应。除此之外,通过趋化因子IP-10诱生IFN-γ阻止肿瘤血管发生。在动物肿瘤模型中,IL-12对移植瘤、化学诱变瘤及自发肿瘤均有明显治疗作用。IL-12可以刺激抗原特异性免疫反应而促进Th1和CTL的消瘤作用。大量的临床治疗肿瘤试验表明,IL-12在抗肿瘤方面效果明显。治疗中出现的不良反应应引起重视,需要制定合理的治疗方案以降低毒副反应确保临床效果。 展开更多
关键词 白细胞介素-12 伽马-干扰素 肿瘤/免疫 临床治疗/免疫 综述文献
下载PDF
尖锐湿疣患者外周血自然杀伤细胞活性的研究 被引量:11
6
作者 李振 曾耀英 +4 位作者 蔡小嫦 何贤辉 徐丽慧 曾山 狄静芳 《中国皮肤性病学杂志》 CAS 北大核心 2003年第3期145-147,共3页
目的 从自然杀伤细胞 (NK)内分泌γ 干扰素和CD6 9表达等层次 ,探讨尖锐湿疣 (CA)患者的细胞免疫状态 ,为临床免疫治疗提供指引。方法 用密度梯度离心法分离出外周血单个核细胞 (PBMC) ,进行细胞培养和免疫荧光染色 :①PDB刺激PBMC ,2... 目的 从自然杀伤细胞 (NK)内分泌γ 干扰素和CD6 9表达等层次 ,探讨尖锐湿疣 (CA)患者的细胞免疫状态 ,为临床免疫治疗提供指引。方法 用密度梯度离心法分离出外周血单个核细胞 (PBMC) ,进行细胞培养和免疫荧光染色 :①PDB刺激PBMC ,2h、12h、2 4h后收获细胞 ,进行anti CD5 6 FITC与anti CD6 9 PE免疫标记 ;②PDB、Ionomycin和Monensin刺激PBMC ,4h收获细胞 ,用anti CD5 6 PE与anti IFN γ FITC细胞内染色 ,最后利用流式细胞仪对标记细胞进行分析。结果 NK细胞受体外刺激后 ,长病程组各时点的CD6 9阳性细胞百分率分别是 ( 2 5 .73± 2 .99) %、( 5 7.0 8±4.74) %、( 6 7.0 7± 2 .5 2 ) % ,与对照组各时点相比较 ,差异均有显著性 (P <0 .0 5 ) ,而短病程组各时点与对照组比较 ,差异均无显著性 (P >0 .0 5 )。长病程组的IFN γ阳性NK细胞比率是 ( 34.6 9± 3 .36 ) % ,与对照组比较差异有显著性 (P <0 .0 5 )。短病程组与对照组比较差异无显著性 (P >0 .0 5 )。结论 短病程患者NK细胞活化和功能均正常 ,但长病程者NK细胞活化明显不足和功能严重障碍。本试验结果为长病程患者的免疫治疗提供理论依据和新的指引。 展开更多
关键词 尖锐湿疣 外周血 自然杀伤细胞活性 γ—干扰素 CD69 细胞免疫状态 临床免疫治疗
下载PDF
Liver alveolar echinococcosis in China: Clinical aspect with relative basic research 被引量:19
7
作者 Ci-Peng Jiang McManus Don Malcolm Jones 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第30期4611-4617,共7页
This paper deals with all aspects of liver alveolar echinococcosis (AE) including epidemiology, pathology, clinical manifestations, imaging examinations, diagnosis and differential diagnosis, surgical treatment and ch... This paper deals with all aspects of liver alveolar echinococcosis (AE) including epidemiology, pathology, clinical manifestations, imaging examinations, diagnosis and differential diagnosis, surgical treatment and chemotherapy.The review is not only based on personal clinical experiences but also in combination with relative basic research such as proliferation and growth of alveococcus, preclinical studies of a novel compound extracted from TCM for treatment of liver AE, and molecular immunology used for specific AE diagnosis, etc. 展开更多
关键词 ECHINOCOCCOSIS Alveolar echinococcosis LIVER Clinical aspect Basic research China
下载PDF
Immunoproteome analysis of soluble and membrane proteins of Shigella flexneri 2457T 被引量:9
8
作者 Amy V Jennison Rubhana Raqib Naresh K Verma 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第41期6683-6688,共6页
AIM: To profile the immunogenic proteins of Shigella flexneri (S. flexneri) expressed during human infection using a proteomic approach. METHODS: Soluble and membrane protein extractions of S. flexneri 2457T were sepa... AIM: To profile the immunogenic proteins of Shigella flexneri (S. flexneri) expressed during human infection using a proteomic approach. METHODS: Soluble and membrane protein extractions of S. flexneri 2457T were separated by two-dimensional gel electrophoresis (2-DE). Proteins were transferred to PVDF membrane and immunoblotted with sera from shigellosis patients. Reactive protein spots were matched to Coomassie stained gels run in parallel, cut out and trypsin digested. Matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS) was used to determine the peptide mass fingerprints, which were searched in the MASCOT database to identify the protein. RESULTS: A total of 8 immunoreactive proteins were successfully identified from the Coomassie stained gels in three repeats. Six of these proteins have not previously been reported as immunogenic in S. flexneri. These proteins could be potential candidates for vaccine or attenuation studies. CONCLUSION: Soluble and membrane proteins of S. flexneri 2457T have been screened by 2-DE and immunoblotting with sera from shigellosis patients. Eight proteins are identified as immunogenic. 展开更多
关键词 Shigella flexneri IMMUNOGENETICS Vaccine antigen Immunoblotting
下载PDF
Crohn’s disease:Innate immunodeficiency? 被引量:7
9
作者 Jesus K Yamamoto-Furusho Joshua R Korzenik 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第42期6751-6755,共5页
In the past, Crohn’s disease (CD) has been understood primarily as an immunologic disorder characterized by an abnormal T-cell response. Recent in vitro and in vivo data suggests that CD may instead be precipitated b... In the past, Crohn’s disease (CD) has been understood primarily as an immunologic disorder characterized by an abnormal T-cell response. Recent in vitro and in vivo data suggests that CD may instead be precipitated by innate immune dysfunction resulting from a combination of genetic and environmental factors. Some reports have demonstrated a defective immune response in a variety of other cellular components, including neutrophils, monocytes and dendritic cells. Recent studies of granulocyte-macrophage colony-stimulating factor (GM- CSF) in CD, aiming to stimulate the innate immune system with the conception that an innate immune defect underlies the development of the disease, have been demonstrated a clinical benefit and reinforce this evolving understanding of the disease. 展开更多
关键词 Crohn's disease Innate immunity IMMUNODEFICIENCY NOD2
下载PDF
T-cell ageing in end-stage renal disease patients:Assessment and clinical relevance 被引量:2
10
作者 Ruud WJ Meijers Michiel GH Betjes +1 位作者 Carla C Baan Nicolle HR Litjens 《World Journal of Nephrology》 2014年第4期268-276,共9页
End-stage renal disease (ESRD) patients have a defec-tive T-cell-mediated immune system which is related to excessive premature ageing of the T-cell compartment. This is likely to be caused by the uremia-associated ... End-stage renal disease (ESRD) patients have a defec-tive T-cell-mediated immune system which is related to excessive premature ageing of the T-cell compartment. This is likely to be caused by the uremia-associated pro-infammatory milieu, created by loss of renal func-tion. Therefore, ESRD patients are highly susceptible for infections, have an increased risk for virus-associated cancers, respond poorly to vaccination and have an increased risk for atherosclerotic diseases. Three ageing parameters can be used to assess an immu-nological T-cell age. First, thymic output can be deter-mined by assessing the T-cell receptor excision circles-content together with CD31 expression within the na?ve T cells. Second, the telomere length of T cells and third the T-cell differentiation status are also indicators of T-cell ageing. Analyses based on these parameters in ESRD patients revealed that the immunological T-cell age is increased by on average 20 years compared to the chronological age. After kidney transplantation (KTx) the aged T-cell phenotype persists although the pro-inflammatory milieu is diminished. This might be explained by epigenetic modifcations at hematopoietic stem cells level. Assessment of an immunological T-cell age could be an important tool to identify KTx recipi-ents who are at risk for allograft rejection or to prevent over-immunosuppression. 展开更多
关键词 End-stage renal disease patients Kidney transplantation T-cell ageing T-cell differentiation UREMIA
下载PDF
Update on immunoglobulin a nephropathy.Part Ⅱ:Clinical,diagnostic and therapeutical aspects 被引量:3
11
作者 Maurizio Salvadori Giuseppina Rosso 《World Journal of Nephrology》 2016年第1期6-19,共14页
Immunoglobulin A nephropathy (IgAN) is characterized by different clinical manifestations and by long-term different outcomes. Major problem for the physicians is to understanding which patients are at risk of a dis... Immunoglobulin A nephropathy (IgAN) is characterized by different clinical manifestations and by long-term different outcomes. Major problem for the physicians is to understanding which patients are at risk of a disease evolution and to prescribe the right therapy to the right patients. Indeed, in addition to patients with a stable disease with no trend to evolution or even with a spontaneous recovery, patients with an active disease and patients with a rapidly evolving glomeru-lonephritis are described. Several histopathological, biological and clinical markers have been described and are currently used to a better understanding of patients at risk, to suggest the right therapy and to monitor the therapy effect and the IgAN evolution over time. The clinical markers are the most reliable and allow to divide the IgAN patients into three categories: The low risk patients, the intermediate risk patients and the high risk patients. Accordingly, the therapeutic measures range from no therapy with the only need of repeated controls, to supportive therapy eventually associated with low dose immunosuppression, to immunosuppressive treat-ment in the attempt to avoid the evolution to end stage renal disease. However the current evidence about the different therapies is still matter of discussion. New drugs are in the pipeline and are described. They are object of randomized controlled trials, but studies with a number of patients adequately powered and with a long follow up are needed to evaluate effcacy and safety of these new drugs. 展开更多
关键词 IgA nephropathy prevention and control IgA nephropathy IgA nephropathy diagnosis IgA nephropathy prognosis IgA nephropathy classifcation IgA nephropathy therapy
下载PDF
Kidney regeneration: Where we are and future perspectives
12
作者 Joao Paulo Zambon Renata S Magalhaes +5 位作者 Inkap Ko Christina L Ross Giuseppe Orlando Andrea Peloso Anthony Atala James J Yoo 《World Journal of Nephrology》 2014年第3期24-30,共7页
In 2012, about 16487 people received kidney transplants in the United States, whereas 95022 candidates were on the waiting list by the end of the year. Despite advances in renal transplant immunology, approximately 40... In 2012, about 16487 people received kidney transplants in the United States, whereas 95022 candidates were on the waiting list by the end of the year. Despite advances in renal transplant immunology, approximately 40% of recipients will die or lose graft within 10 years. The limitations of current therapies for renal failure have led researchers to explore the development of modalities that could improve, restore, or replace the renal function. The aim of this paper is to describe a reasonable approach for kidney regeneration and review the current literature regarding cell sources and mechanisms to develop a bioengineering kidney. Due to kidneys peculiar anatomy, extracellular matrix based scaffolds are rational starting point for their regeneration. The perfusion of detergents through the kidney vasculature is an effcient method for delivering decel-lularizing agents to cells and for removing of cellular material from the tissue. Many efforts have focused on the search of a reliable cell source to provide enrichment for achieving stable renal cell systems. For an effcient bioengineered kidney, these cells must be attached to the organ and then maturated into the bio-ractors, which simulates the human body environment.A functional bioengineered kidney is still a big challenge for scientists. In the last ten years we have got many improvements on the feld of solid organ regeneration; however, we are still far away from the main target. Currently, regenerative centers worldwide have been striving to find feasible strategies to develop bioengi-neered kidneys. Cell-scaffold technology gives hope to end-stage renal disease patients who struggle with morbidity and mortality due to extended periods on dialysis or immunosupression. The potential of bioengi-neered organ is to provide a reliable source of organs, which can be refunctionalized and transplanted. 展开更多
关键词 Kidney regeneration Stem cells DECELLULARIZATION Extra cellular matrix Regenerative medicine
下载PDF
Progress in Drug Therapy for Multiple Myeloma
13
作者 Shun'e Yang Bing Zhao 《Chinese Journal of Clinical Oncology》 CSCD 2008年第4期251-257,共7页
Multiple myeloma remains incurable with conventional treatments.However,new active drugs,including the immunomodulatory agents,thalidomide and lenalidomide, and the proteasome inhibitors bortezomib and NPI-0052,and ot... Multiple myeloma remains incurable with conventional treatments.However,new active drugs,including the immunomodulatory agents,thalidomide and lenalidomide, and the proteasome inhibitors bortezomib and NPI-0052,and other targeted therapies,have shown promising anti-myeloma activity.These agents represent a new generation of treatments for multiple myeloma that affect both specific intracellular signaling pathways and the tumor microenvironment.This review therefore focuses on the extensive clinical data available from studies of these drugs in the treatment of newly diagnosed,refractory and relapsed multiple myeloma. 展开更多
关键词 multiple myeloma THERAPY IMMUNOMODULATORY proteasome inhibitor targeted therapies.
下载PDF
Diagnosis and therapy of primary lung diffuse large B cell lymphoma: a case report
14
作者 Lei Zhou Li Duan Min Hu 《The Chinese-German Journal of Clinical Oncology》 CAS 2009年第8期492-494,共3页
Objective: We studied the diagnosis and therapy of primary lung diffuse large B cell lymphoma (DLBCL). Methods: Analysis the clinical manifestations, pathologic character and immunohistochemical character of one l... Objective: We studied the diagnosis and therapy of primary lung diffuse large B cell lymphoma (DLBCL). Methods: Analysis the clinical manifestations, pathologic character and immunohistochemical character of one lung diffuse B cell lymphoma patent. Results: In visual observation, it's a gray irregular fobulated mass, section was gray, fish-like, and number of necrotic foci. Observed under the microscope, subepithelial respiratory center oocyte-like cells diffuse proliferative, infiltration in lung tissue. Immunohistochemistry: CD20 (+), CD79a (+), CD3 (-), CD45RO (-), PCK (-). Conclusion: Diffuse large B cell lymphoma is the most common subtype in non-Hodgkin lymphoma, but the primary lung diffuse large B cell lymphoma is rare. This disease is lack of typical clinical manifestations, so easily misdiagnosed. The diagnosis of diffuse large B cell lymphoma should be based on pathology and immunohistochemistry. 展开更多
关键词 LUNG diffuse large B cell lymphoma DIAGNOSE THERAPY
下载PDF
抗HLA抗体在同种大动脉移植后的免疫表达
15
作者 张刚 张广福 郑晓舟 《中华胸心血管外科杂志》 CSCD 北大核心 2005年第5期280-281,共2页
关键词 抗HLA抗体 同种瓣 移植后 大动脉 免疫表达 体液免疫反应 临床免疫治疗 临床的应用 低温保存
原文传递
NK cell-based cancer immunotherapy: from basic biology to clinical application 被引量:14
16
作者 LI Yang YIN Jie +4 位作者 LI Ting HUANG Shan YAN Han LEAVENWORTH Jian Mei WANG Xi 《Science China(Life Sciences)》 SCIE CAS CSCD 2015年第12期1233-1245,共13页
Natural killer(NK) cells, which recognize and kill target cells independent of antigen specificity and major histocompatibility complex(MHC) matching, play pivotal roles in immune defence against tumors. However, tumo... Natural killer(NK) cells, which recognize and kill target cells independent of antigen specificity and major histocompatibility complex(MHC) matching, play pivotal roles in immune defence against tumors. However, tumor cells often acquire the ability to escape NK cell-mediated immune surveillance. Thus, understanding mechanisms underlying regulation of NK cell phenotype and function within the tumor environment is instrumental for designing new approaches to improve the current cell-based immunotherapy. In this review, we elaborate the main biological features and molecular mechanisms of NK cells that pertain to regulation of NK cell-mediated anti-tumor activity. We further overview current clinical approaches regarding NK cell-based cancer therapy, including cytokine infusion, adoptive transfer of autologous or allogeneic NK cells, applications of chimeric antigen receptor(CAR)-expressing NK cells and adoptive transfer of memory-like NK cells. With these promising clinical outcomes and fuller understanding the basic questions raised in this review, we foresee that NK cell-based approaches may hold great potential for future cancer immunotherapy. 展开更多
关键词 NK cell CANCER cytokine infusion adoptive transfer IMMUNOTHERAPY
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部